Brean Murray Reverses On Medivation (MDVN); Upgrades to Buy and Sees Another 100%+ Upside
Tweet Send to a FriendGet Alerts MDVN Hot Sheet
Price: $47.41 -6.78%
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 24 | Down: 17 | New: 24
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 24 | Down: 17 | New: 24
Trade MDVN Now!
Brean Murray Carret & Co. upgraded Medivation (NASDAQ: MDVN) from Sell to Buy and raises their price target from $6 to $77.
The firm comments, "Every argument we made for why MDV3100 should have failed only makes the drug appear stronger. We are therefore reversing our thesis on Medivation, despite the stock having more than doubled already today because for a monitoring committee to stop a trial early we believe that a thorough risk/reward analysis was conducted and thus our concern over safety issues cropping up in future detailed data disclosures is minimized."
Even with shares up 120 percent today, the firm's new price target suggests another 111 percent upside.
For more ratings news on Medivation click here and for the rating history of Medivation click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "Every argument we made for why MDV3100 should have failed only makes the drug appear stronger. We are therefore reversing our thesis on Medivation, despite the stock having more than doubled already today because for a monitoring committee to stop a trial early we believe that a thorough risk/reward analysis was conducted and thus our concern over safety issues cropping up in future detailed data disclosures is minimized."
Even with shares up 120 percent today, the firm's new price target suggests another 111 percent upside.
For more ratings news on Medivation click here and for the rating history of Medivation click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Oppenheimer Upgrades GameStop (GME) to Outperform
- Canaccord Genuity Upgrades Rogers Communications (RCI) to Buy
- William Blair Upgrades Blue Nile (NILE) to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
Brean Murray Carret & Co.
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
